相似文献
1
Clinical Implications of an Acute Dip in eGFR after SGLT2 Inhibitor Initiation.
Clin J Am Soc Nephrol. 2021 Aug;16(8):1278-1280. doi: 10.2215/CJN.02480221. Epub 2021 Apr 20.
2
The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
Kidney Blood Press Res. 2019;44(2):149-157. doi: 10.1159/000498963. Epub 2019 Apr 2.
3
Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis.
Diabetes Obes Metab. 2019 Feb;21(2):340-348. doi: 10.1111/dom.13532. Epub 2018 Oct 15.
4
Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II-dependent kidney damage.
BMC Nephrol. 2019 Aug 2;20(1):292. doi: 10.1186/s12882-019-1490-z.
5
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.
Curr Diab Rep. 2022 Jan;22(1):39-52. doi: 10.1007/s11892-021-01442-z. Epub 2022 Feb 3.
6
Acute kidney injury from SGLT2 inhibitors: potential mechanisms.
Nat Rev Nephrol. 2016 Nov 16;12(12):711-712. doi: 10.1038/nrneph.2016.159.
7
Acute and Direct Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glomerular Filtration Rate in Spontaneously Diabetic Torii Fatty Rats.
Biol Pharm Bull. 2019;42(10):1707-1712. doi: 10.1248/bpb.b19-00351.
8
eGFR Decline after SGLT2 Inhibitor Initiation: The Tortoise and the Hare Reimagined.
Kidney360. 2021 Mar 26;2(6):1042-1047. doi: 10.34067/KID.0001172021. eCollection 2021 Jun 24.
9
Renal Effects of Sodium-Glucose Co-Transporter Inhibitors.
Am J Cardiol. 2019 Dec 15;124 Suppl 1(Suppl 1):S28-S35. doi: 10.1016/j.amjcard.2019.10.027.
10
Renal effects of SGLT2 inhibitors: an update.
Curr Opin Nephrol Hypertens. 2020 Mar;29(2):190-198. doi: 10.1097/MNH.0000000000000584.
引用本文的文献
1
Continuation Versus Discontinuation of Sodium-Glucose Cotransporter-2 Inhibitors and Cardiorenal Outcomes Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A Nationwide Cohort Study With a Target Trial Emulation Framework.
Clin Transl Sci. 2025 Aug;18(8):e70319. doi: 10.1111/cts.70319.
2
Initial change in fractional excretion of total protein after SGLT2 inhibitors predicts renal prognosis in patients with chronic kidney disease.
Clin Kidney J. 2025 Jul 7;18(8):sfaf209. doi: 10.1093/ckj/sfaf209. eCollection 2025 Aug.
3
Finerenone and Estimated GFR Slope in Type 2 Diabetes and CKD.
Kidney Int Rep. 2025 Apr 14;10(7):2461-2465. doi: 10.1016/j.ekir.2025.04.012. eCollection 2025 Jul.
4
The Future of Chronic Kidney Disease Treatment: Combination Therapy (Polypill) or Biomarker-Guided Personalized Intervention?
Biomolecules. 2025 Jun 3;15(6):809. doi: 10.3390/biom15060809.
5
Gliflozins in hypertension: basic mechanisms and clinical insights.
Am J Physiol Renal Physiol. 2025 Jul 1;329(1):F32-F45. doi: 10.1152/ajprenal.00119.2025. Epub 2025 May 27.
6
Sodium-glucose co-transporter 2 inhibitors: Prospects for canine myxomatous mitral valve disease and finding the "right drug" and the "right dose" for dogs.
J Vet Med Sci. 2025 Jun 1;87(6):647-666. doi: 10.1292/jvms.25-0040. Epub 2025 Apr 16.
7
A review of the safety of sodium-glucose co-transporter-2 inhibitors.
Diabetes Obes Metab. 2025 Jul;27(7):3598-3606. doi: 10.1111/dom.16385. Epub 2025 Apr 8.
8
Sodium-Glucose Cotransporter 2 Inhibitors in Patients Undergoing Coronary Angiography: A Randomized Controlled Trial (BELIEVE Trial).
Kidney360. 2025 Mar 21;6(8):1317-1327. doi: 10.34067/KID.0000000781.
9
Kidney hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in diabetes: physiology and clinical implications.
Clin Kidney J. 2024 Nov 27;18(1):sfae370. doi: 10.1093/ckj/sfae370. eCollection 2025 Jan.
10
Modeling Cardiorenal Protection with Sodium-Glucose Cotransporter 2 Inhibition in Type 1 Diabetes: An Analysis of DEPICT-1 and DEPICT-2.
Clin J Am Soc Nephrol. 2025 Apr 1;20(4):529-538. doi: 10.2215/CJN.0000000641. Epub 2025 Feb 7.
Zotero 插件